Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Security class unavailable · CUSIP: 03753U106

Event date: 2020-01-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
10,282,630
Percent of class
13.7400%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902219-20-000352
Form type
SC 13G/A
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Feb 10, 2020
Reporting period
Jan 31, 2020
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub